About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Consumer Reports: GSK-Roche Boniva Ads Are "Misleading"

By Jim Edwards | May 5, 2009

Consumer Reports says TV commercials for Roche and GlaxoSmithKline’s Boniva osteoporosis treatment are “misleading.” (Video below.)

The watchdog group has road-tested a bunch of drug ads and not liked what it found. The CR format is amusing — they play sections of the ad and CR associate editor Jamie Kopf Hirsch provides a sarcastic commentary.

In terms of the Boniva ads, which featureactress Sally Field, CR said that the ad could have been more forthcoming about the price of the drug and the fact that it is not more effective than generic alternatives. CR:

… that convenience comes at a price—it can set you back about 10 times the cost of the similar drug alendronate (the generic version of Fosamax).

… studies don’t show that Boniva is any more effective than other bisphosphonates. So unless you absolutely can’t tolerate a weekly dosing schedule, it makes sense to try the generic first, even if it means you won’t take the same drug as Sally.

CR has also looked at ads for Seasonique, Cialis, Rozerem, and Requip.

DTC Perspectives’ Bob Ehrlich isn’t a fan of the series:

The web piece is titled “Sally Field and Boniva-Great spokeswoman, misleading ad.” I could not find anything which supported the “misleading” portion in the title.

… I guess Ms. Hirsh would like the Boniva ad to point out that other drugs are available at lower cost. I think it would be nice if all companies told you what else is available from competitors, but then that would not be advertising.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • Corrections: Swine-flu fears grow

    MarketWatch - 211 days 7 hours 5 minutes ago

    On April 27, a MarketWatch report on an outbreak of the swine flu misidentified the treatments from drugmakers Roche Holding Ltd. (RHHB.Y:RHHB.YNews , chart , profile , moreLast: (RHHB.Y:RHHB.YNews , chart , profile ,Delayed quote dataAdd to portfolioAnalystDelayed quote dataAdd...

  • Amgen/GSK teaming up on Denosumab marketing

    Medical Marketing and Media - 119 days 16 hours 23 minutes ago

    Amgen and GlaxoSmithKline (GSK) announced plans to share commercialization of Amgen's osteoporosis drug denosumab, in Europe, Australia, New Zealand and Mexico once they win approval in those countries.Amgen will commercialize the drug for postmenopausal osteoporosis and oncology in the US and Canada and for all oncology indications in Europe...

  • Flu treatment output 'to triple'

    BBC - 125 days 15 hours 33 minutes ago

    Drugs giant GlaxoSmithKline says it expects to triple capacity of its flu treatment Relenza to 190 million treatments per year. Glaxo also said it had received contracts for 195 million doses of the H1N1 vaccine for swine flu, adding that it was on track to meet the orders. It said it was involved in continuing talks with more than 50...

  • GlaxoSmithKline supports Panadol with TV campaign

    Marketing Magazine - 141 days 17 hours 23 minutes ago

    The ads, which break on 13 July and run through August, are part of a £3.7m spend on the brand during 2009. They will be supported by online banner ads and a consumer website, www.mypainrelief.co.uk. It is the second TV campaign for Panadol Advance this year. GSK said the TV debut in February had helped boost sales and the new phase of support...

  • Amgen Partners with Glaxo to Distribute Prize Pipeline Product

    Seeking Alpha - 119 days 9 hours 6 minutes ago

    EP Vantage submits: Amgen AMGN has finally revealed its commercialisation strategy for osteoporosis treatment, denosumab, one of the most keenly anticipated new drugs set to reach the market for several years, naming GlaxoSmithKline GSK as partner in Europe and other countries. The antibody is considered the most valuable pipeline

 
Reply to Story

BNET TalkbackShare your ideas and expertise on this topic

Subscribe to this discussion via Email or RSS

  •  
    1

    chris.pounds@...

    05/05/09 | Report as spam

    RE: Consumer Reports: GSK-Roche Boniva Ads Are

    The compliance issue that she mentions at the end is
    interesting. I wonder if it can be shown that the differential
    compliance leads in this class leads to better overall outcomes.

  •  
    2

    BNET's Jim Edwards

    05/05/09 | Report as spam

    RE: Consumer Reports: GSK-Roche Boniva Ads Are

    @chris.pounds@...

    interesting. Assume that it does: Should there be a duty on advertisers to disclose that? Seems somewhat harsh...

    Jim Edwards, BNET.

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
Click Here
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here